← Back to 4-HO-MiPT

4-HO-MiPT Stats & Data

Psychedelic Research-chemical

4-ho Ho-mipt Miprocin 4homipt homipt

Chemical Class Phenethylamine

Psychoactive Class Psychedelic

Effect Profile

Curated + 118 Reports

Psychedelic 8.8

Strong visuals, headspace, auditory effects, and body load

Visual Intensity×3

10103.9

Headspace Depth×3

109.52.3

Auditory Effects×1

10102.7

Body Load / Somatic Effects×1

10105.5

Catalog Erowid BlueLight

Based on reports from:

Effect Index The Essence of Bugs — nervewing Effect Index A Delightfully Fun and Clear-Headed Psychedelic — froggie TiHKAL TiHKAL #22: 4-HO-MIPT Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 4-HO-MiPT

Community Effects

TripSit

Positive

visual enhancement euphoria body high music enhancement

Negative

nausea body load anxiety

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 10d Baseline ~14d

Cross-Tolerances

LSD

80% ●○○

Psilocybin

85% ●○○

Psilocin

85% ●○○

Mescaline

65% ●○○

DMT

85% ●○○

5-MeO-DMT

85% ●○○

2C-B

65% ●○○

2C-E

65% ●○○

Experience Report Analysis

Erowid BlueLight

81 Reports

2004–2024 Date Range

59 With Age Data

32 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 118 experience reports (81 Erowid + 37 Bluelight)

118 Reports

149 Effects Detected

73 Positive

52 Adverse

24 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 73

Music Enhancement 56.7% 88%

Color Enhancement 50.0% 88%

Stimulation 41.5% 83%

Visual Trails 37.8% 89%

Euphoria 36.4% 93%

Empathy 33.1% 84%

Tactile Enhancement 27.1% 83%

Introspection 27.1% 80%

Surface Breathing 27.0% 84%

Joy 27.0% 88%

Focus Enhancement 26.2% 80%

Body High 22.9% 86%

Contentment 21.6% 85%

Awe 21.6% 79%

Geometric Imagery 21.6% 86%

Libido Enhancement 21.6% 84%

Patterning 18.9% 86%

Melting/flowing 16.2% 85%

Insight 16.2% 82%

Fractal Imagery 13.5% 90%

Adverse Effects 52

Anxiety 45.7% 81%

Body Load 40.5% 77%

Nausea 33.0% 79%

Muscle Tension 32.2% 78%

Confusion 25.4% 82%

Tremor 16.2% 81%

Paranoia 16.2% 85%

Thought Disorganization 16.2% 82%

Jaw Clenching 14.4% 80%

Motor Impairment 12.7% 77%

Memory Suppression 11.9% 85%

Headache 11.0% 80%

Temporal Disorientation 10.8% 84%

Depersonalization 10.8% 80%

Fear 10.8% 85%

Sweating 10.1% 80%

Increased Heart Rate 9.9% 70%

Insomnia 8.1% 80%

Psychosis 6.2% 70%

Thought Loops 5.9% 80%

Dose-Response Correlation

How effect frequency changes across dose levels

View data table

Effect	Light (n=11)	Common (n=21)	Strong (n=19)	Heavy (n=10)
Visual Distortions	90.9%	90.5%	100.0%	80.0%
Music Enhancement	72.7%	66.7%	89.5%	40.0%
Color Enhancement	54.5%	57.1%	84.2%	40.0%
Stimulation	54.5%	38.1%	73.7%	40.0%
Anxiety	63.6%	42.9%	52.6%	60.0%
Euphoria	54.5%	42.9%	57.9%	20.0%
Muscle Tension	45.5%	57.1%	36.8%	40.0%
Closed-Eye Visuals	54.5%	38.1%	47.4%	50.0%
Empathy	54.5%	38.1%	42.1%	30.0%
Auditory Effects	36.4%	42.9%	52.6%	30.0%
Tactile Enhancement	27.3%	38.1%	52.6%	30.0%
Nausea	27.3%	47.6%	36.8%	50.0%
Open-Eye Visuals	18.2%	28.6%	21.1%	50.0%
Focus Enhancement	36.4%	28.6%	47.4%	30.0%
Jaw Clenching	0%	14.3%	21.1%	40.0%

Dose–Effect Mapping

Experience Reports

How reported effects shift across dose tiers, based on 81 experience reports.

Oral dose range: 16.0–30.0 mg (median 22.0 mg)

Effect	Light (n=11)	Common (n=21)	Strong (n=19)	Heavy (n=10)
visual distortions	91%	90%	100%	80%	→
music enhancement	73%	67%	90%	40%	↓
color enhancement	54%	57%	84%	40%	↓
stimulation	54%	38%	74%	40%	↓
anxiety	64%	43%	53%	60%	→
euphoria	54%	43%	58%	20%	↓
muscle tension	46%	57%	37%	40%	→
closed-eye visuals	54%	38%	47%	50%	→
empathy	54%	38%	42%	30%	↓
auditory effects	36%	43%	53%	30%	↓
tactile enhancement	27%	38%	53%	30%	→
nausea	27%	48%	37%	50%	↑
open-eye visuals	18%	29%	21%	50%	↑
focus enhancement	36%	29%	47%	30%	↓
jaw clenching	—	14%	21%	40%	↑
confusion	27%	38%	37%	30%	→
dissociation	—	38%	16%	30%	↓
body high	27%	10%	37%	20%	↓
sedation	18%	33%	32%	30%	↑
introspection	27%	24%	32%	20%	↓

Showing top 20 of 30 effects

Risk Escalation

Sentiment Analysis

Average frequency of positive vs adverse effects across dose tiers

Light n=11

9 positive 45.4% 6 adverse 34.9%

Common n=21

10 positive 35.7% 9 adverse 28.6%

Strong n=19

10 positive 53.7% 11 adverse 27.8%

Heavy n=10

9 positive 30.0% 5 adverse 44.0%

View effect breakdown

Adverse Effects

Effect	Light (n=11)	Common (n=21)	Strong (n=19)	Heavy (n=10)	Change
Anxiety	64%	43%	53%	60%	-5%
Muscle Tension	46%	57%	37%	40%	-12%
Nausea	27%	48%	37%	50%	+83%
Jaw Clenching	—	14%	21%	40%	+179%
Confusion	27%	38%	37%	30%	9%
Headache	27%	14%	21%	—	-22%
Sweating	—	—	26%	—	0%
Motor Impairment	18%	19%	21%	—	+15%
Memory Suppression	—	14%	21%	—	+47%
Increased Heart Rate	—	—	21%	—	0%
Thought Loops	—	10%	10%	—	10%

Positive Effects

Effect	Light (n=11)	Common (n=21)	Strong (n=19)	Heavy (n=10)	Change
Music Enhancement	73%	67%	90%	40%	-44%
Color Enhancement	54%	57%	84%	40%	-26%
Stimulation	54%	38%	74%	40%	-26%
Euphoria	54%	43%	58%	20%	-63%
Empathy	54%	38%	42%	30%	-44%
Tactile Enhancement	27%	38%	53%	30%	9%
Focus Enhancement	36%	29%	47%	30%	-17%
Body High	27%	10%	37%	20%	-26%
Introspection	27%	24%	32%	20%	-26%
Creativity Enhancement	—	14%	21%	—	+47%

Dosage Distribution

Dose distribution from experience reports

Median: 22.0 mg IQR: 16.0–30.0 mg n=55

Real-World Dose Distribution

62K Doses

From 119 individual dose entries

Oral (n=96)

Median: 20.0mg 25th: 15.0mg 75th: 27.25mg 90th: 30.5mg

mg/kg median: 0.302 mg/kg 75th: 0.408

Insufflated (n=13)

Median: 10.0mg 25th: 6.0mg 75th: 15.0mg 90th: 20.0mg

mg/kg median: 0.182 mg/kg 75th: 0.315

Common Combinations

Most co-occurring substances in experience reports

Form / Preparation

Most common forms and preparations reported

Body-Weight Dosing

Dose relative to body weight from reports with weight data

Median: 0.317 mg/kg IQR: 0.232–0.406 mg/kg n=53

Redose Patterns

Redosing behavior across 68 reports

19.1% Redosed

1.3 Avg Doses

30m Median Interval

Read full reports on Erowid →

← Back to 4-HO-MiPT